| Dr Nabeeh Naufal Lahood, MD | |
|
1500 N Wilmot Rd Ste A110, Tucson, AZ 85712-4416 | |
| (520) 318-1860 | |
| (520) 318-1859 |
| Full Name | Dr Nabeeh Naufal Lahood |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 26 Years |
| Location | 1500 N Wilmot Rd Ste A110, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043314065 | NPI | - | NPPES |
| 044975 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 20113 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tucson Medical Center | Tucson, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy Asthma Associates Pc | 2163408667 | 3 |
News Archive
An expert committee have recommended that the U.S. government allows the clinical investigation of mitochondrial replacement techniques (MRT) to go ahead.
Interactions between proteins are at the heart of cellular processes, and those interactions depend on the interfaces where the direct physical contact occurs. A new study published this week suggests that there may be roughly a thousand structurally-distinct protein-protein interfaces - and that their structures depend largely on the simple physics of the proteins.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
A new study found an inverse association between socioeconomic status and certain kidney diseases. The findings appear in an upcoming issue of CJASN.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.
› Verified 6 days ago
| Entity Name | Allergy Asthma Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831290766 PECOS PAC ID: 2163408667 Enrollment ID: O20040625000587 |
News Archive
An expert committee have recommended that the U.S. government allows the clinical investigation of mitochondrial replacement techniques (MRT) to go ahead.
Interactions between proteins are at the heart of cellular processes, and those interactions depend on the interfaces where the direct physical contact occurs. A new study published this week suggests that there may be roughly a thousand structurally-distinct protein-protein interfaces - and that their structures depend largely on the simple physics of the proteins.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
A new study found an inverse association between socioeconomic status and certain kidney diseases. The findings appear in an upcoming issue of CJASN.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nabeeh Naufal Lahood, MD 1500 N Wilmot Rd Ste A110, Tucson, AZ 85712-4416 Ph: (520) 318-1860 | Dr Nabeeh Naufal Lahood, MD 1500 N Wilmot Rd Ste A110, Tucson, AZ 85712-4416 Ph: (520) 318-1860 |
News Archive
An expert committee have recommended that the U.S. government allows the clinical investigation of mitochondrial replacement techniques (MRT) to go ahead.
Interactions between proteins are at the heart of cellular processes, and those interactions depend on the interfaces where the direct physical contact occurs. A new study published this week suggests that there may be roughly a thousand structurally-distinct protein-protein interfaces - and that their structures depend largely on the simple physics of the proteins.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
A new study found an inverse association between socioeconomic status and certain kidney diseases. The findings appear in an upcoming issue of CJASN.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.
› Verified 6 days ago
Dr. Nicole Anne Lahood, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1500 N Wilmot Rd Ste A110, Tucson, AZ 85712 Phone: 520-318-1860 Fax: 520-318-1859 | |
Dr. Gerald Bruce Goldstein, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 2320 N Wyatt Dr, Suite 71, Tucson, AZ 85712 Phone: 520-318-1860 Fax: 520-318-1859 | |
Kudagal S Murthy, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2902 E Grant Rd, Tucson, AZ 85716 Phone: 520-322-8361 Fax: 520-322-8462 | |
Dr. Douglas Min, M.D. Allergy & Immunology Medicare: May Accept Medicare Assignments Practice Location: 2902 E Grant Rd, Tucson, AZ 85716 Phone: 520-322-8361 | |
Dr. Martin Hans Bartels, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 6565 E Carondelet Dr, Ste 335, Tucson, AZ 85710 Phone: 520-722-2022 Fax: 520-290-6175 | |
George J Makol, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2902 E Grant Rd, Tucson, AZ 85716 Phone: 520-322-8361 Fax: 520-322-8462 |